AI Chat Paper
Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
Search articles, authors, keywords, DOl and etc.
{{expandStatus?'Exit ':''}}Advanced Search
Numerous therapeutic anti-tumor strategies have been developed in recent decades. However, their therapeutic efficacy is reduced by the intrinsic protective autophagy of tumors. Autophagy plays a key role in tumorigenesis and tumor treatment, in which the overproduction of reactive oxygen species (ROS) is recognized as the direct cause of protective autophagy. Only a few molecules have been employed as autophagy inhibitors in tumor therapy to reduce protective autophagy. Among them, hydroxychloroquine is the most commonly used autophagy inhibitor in clinics, but it is severely limited by its high therapeutic dose, significant toxicity, poor reversal efficacy, and nonspecific action. Herein, we demonstrate a reductive-damage strategy to enable tumor therapy by the inhibition of protective autophagy via the catalytic scavenging of ROS using porous nanorods of ceria (PN-CeO2) nanozymes as autophagy inhibitor. The antineoplastic effects of PN-CeO2 were mediated by its high reductive activity for intratumoral ROS degradation, thereby inhibiting protective autophagy and activating apoptosis by suppressing the activities of phosphatidylinositide 3-kinase/protein kinase B and p38 mitogen-activated protein kinase pathways in human cutaneous squamous cell carcinoma. Further investigation highlighted PN-CeO2 as a safe and efficient anti-tumor autophagy inhibitor. Overall, this study presents a reductive-damage strategy as a promising anti-tumor approach that catalytically inhibits autophagy and activates the intrinsic antioxidant pathways of tumor cells and also shows its potential for the therapy of other autophagy-related diseases.
Helleday, T. Poisoning cancer cells with oxidized nucleosides. N. Engl. J. Med. 2015, 373, 1570–1571.
Perillo, B.; Di Donato, M.; Pezone, A.; Di Zazzo, E.; Giovannelli, P.; Galasso, G.; Castoria, G.; Migliaccio, A. ROS in cancer therapy: The bright side of the moon. Exp. Mol. Med. 2020, 52, 192–203.
Galadari, S.; Rahman, A.; Pallichankandy, S.; Thayyullathil, F. Reactive oxygen species and cancer paradox: To promote or to suppress? Free Radic. Biol. Med. 2017, 104, 144–164.
Yang, H. T.; Villani, R. M.; Wang, H. L.; Simpson, M. J.; Roberts, M. S.; Tang, M.; Liang, X. W. The role of cellular reactive oxygen species in cancer chemotherapy. J. Exp. Clin. Cancer Res. 2018, 37, 266.
Liu, C.; Lin, Q.; Yun, Z. Cellular and molecular mechanisms underlying oxygen-dependent radiosensitivity. Radiat. Res. 2015, 183, 487–496.
Pham, T. C.; Nguyen, V. N.; Choi, Y.; Lee, S.; Yoon, J. Recent strategies to develop innovative photosensitizers for enhanced photodynamic therapy. Chem. Rev. 2021, 121, 13454–13619.
He, G. L.; Xu, N.; Ge, H. Y.; Lu, Y.; Wang, R.; Wang, H. X.; Du, J. J.; Fan, J. L.; Sun, W.; Peng, X. J. Red-light-responsive Ru complex photosensitizer for lysosome localization photodynamic therapy. ACS Appl. Mater. Interfaces 2021, 13, 19572–19580.
Yang, B. W.; Chen, Y.; Shi, J. L. Reactive oxygen species (ROS)-based nanomedicine. Chem. Rev. 2019, 119, 4881–4985.
Chen, J. J.; Zhu, Y. F.; Wu, C. T.; Shi, J. L. Nanoplatform-based cascade engineering for cancer therapy. Chem. Soc. Rev. 2020, 49, 9057–9094.
Canaparo, R.; Foglietta, F.; Limongi, T.; Serpe, L. Biomedical applications of reactive oxygen species generation by metal nanoparticles. Materials (Basel) 2021, 14, 53.
Wang, X. W.; Zhong, X. Y.; Liu, Z.; Cheng, L. Recent progress of chemodynamic therapy-induced combination cancer therapy. Nano Today 2020, 35, 100946.
He, Y. X.; Liu, S. H.; Yin, J.; Yoon, J. Sonodynamic and chemodynamic therapy based on organic/organometallic sensitizers. Coord. Chem. Rev. 2021, 429, 213610.
Zhang, C. Y.; Wang, X.; Du, J. F.; Gu, Z. J.; Zhao, Y. L. Reactive oxygen species-regulating strategies based on nanomaterials for disease treatment. Adv. Sci. 2021, 8, 2002797.
Wang, X. Q.; Wang, W. J.; Peng, M. Y.; Zhang, X. Z. Free radicals for cancer theranostics. Biomaterials 2021, 266, 120474.
Fan, W. P.; Yung, B.; Huang, P.; Chen, X. Y. Nanotechnology for multimodal synergistic cancer therapy. Chem. Rev. 2017, 117, 13566–13638.
Yang, J. Y.; Zhao, Y.; Zhou, Y. Y.; Wei, X. L.; Wang, H. J.; Si, N.; Yang, J.; Zhao, Q. H.; Bian, B. L.; Zhao, H. Y. Advanced nanomedicines for the regulation of cancer metabolism. Biomaterials 2022, 286, 121565.
Wang, M.; Chang, M. Y.; Li, C. X.; Chen, Q.; Hou, Z. Y.; Xing, B. G.; Lin, J. Tumor-microenvironment-activated reactive oxygen species amplifier for enzymatic cascade cancer starvation/chemodynamic/immunotherapy. Adv. Mater. 2022, 34, 2106010.
Zhang, X. H.; Guo, R. C.; Chen, Y. F.; Xu, X.; Yang, Z. X.; Cheng, D. B.; Chen, H.; Qiao, Z. Y.; Wang, H. A BiOCl nanodevice for pancreatic tumor imaging and mitochondria-targeted therapy. Nano Today 2021, 40, 101285.
Filomeni, G.; De Zio, D.; Cecconi, F. Oxidative stress and autophagy: The clash between damage and metabolic needs. Cell. Death. Differ. 2015, 22, 377–388.
Xia, H. J.; Green, D. R.; Zou, W. P. Autophagy in tumour immunity and therapy. Nat. Rev. Cancer 2021, 21, 281–297.
Doherty, J.; Baehrecke, E. H. Life, death and autophagy. Nat. Cell Biol. 2018, 20, 1110–1117.
Huang, J.; Brumell, J. H. Bacteria-autophagy interplay: A battle for survival. Nat. Rev. Microbiol. 2014, 12, 101–114.
Galluzzi, L.; Green, D. R. Autophagy-independent functions of the autophagy machinery. Cell 2019, 177, 1682–1699.
Stukalov, A.; Girault, V.; Grass, V.; Karayel, O.; Bergant, V.; Urban, C.; Haas, D. A.; Huang, Y. Q.; Oubraham, L.; Wang, A. Q. et al. Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV. Nature 2021, 594, 246–252.
Yamazaki, T.; Pedro, J. M. B. S.; Galluzzi, L.; Kroemer, G.; Pietrocola, F. Autophagy in the cancer-immunity dialogue. Adv. Drug Deliv. Rev. 2021, 169, 40–50.
Wang, L.; Wang, Y. T.; Zhao, W.; Lin, K. L.; Li, W.; Wang, G. D.; Zhang, Q. Library screening to identify highly-effective autophagy inhibitors for improving photothermal cancer therapy. Nano Lett. 2021, 21, 9476–9484.
Gao, G.; Sun, X. B.; Liu, X. Y.; Jiang, Y. W.; Tang, R. Q.; Guo, Y. X.; Wu, F. G.; Liang, G. L. Intracellular nanoparticle formation and hydroxychloroquine release for autophagy-inhibited mild-temperature photothermal therapy for tumors. Adv. Funct. Mater. 2021, 31, 2102832.
Wang, X. H.; Li, M.; Ren, K. B.; Xia, C. Y.; Li, J. P.; Yu, Q. W.; Qiu, Y.; Lu, Z. Z.; Long, Y.; Zhang, Z. R. et al. On-demand autophagy cascade amplification nanoparticles precisely enhanced oxaliplatin-induced cancer immunotherapy. Adv. Mater. 2020, 32, 2002160.
Xie, Y. X.; Jiang, J. N.; Tang, Q. Y.; Zou, H. B.; Zhao, X.; Liu, H. M.; Ma, D.; Cai, C. L.; Zhou, Y.; Chen, X. J. et al. Iron oxide nanoparticles as autophagy intervention agents suppress hepatoma growth by enhancing tumoricidal autophagy. Adv. Sci. 2020, 7, 1903323.
Shashni, B.; Nagasaki, Y. Nitroxide radical-containing nanoparticles attenuate tumorigenic potential of triple negative breast cancer. Biomaterials 2018, 178, 48–62.
Wang, J. F.; Zhou, X. F.; Wang, H. F.; Xiao, Q.; Ding, K. F.; Dong, X.; Xu, S. F.; Shen, B.; Sun, J. H.; Zhou, Z. X. et al. Autophagy-inhibiting polymer as an effective nonviral cancer gene therapy vector with inherent apoptosis-sensitizing ability. Biomaterials 2020, 255, 120156.
Kim, K. Y.; Park, K. I.; Kim, S. H.; Yu, S. N.; Park, S. G.; Kim, Y. W.; Seo, Y. K.; Ma, J. Y.; Ahn, S. C. Inhibition of autophagy promotes salinomycin-induced apoptosis via reactive oxygen species-mediated PI3K/AKT/mTOR and ERK/p38 MAPK-dependent signaling in human prostate cancer cells. Int. J. Mol. Sci. 2017, 18, 1088.
Xu, J.; Wang, H. S.; Hu, Y.; Zhang, Y. S.; Wen, L. P.; Yin, F.; Wang, Z. Y.; Zhang, Y. C.; Li, S. Y.; Miao, Y. Y. et al. Inhibition of CaMKIIα activity enhances antitumor effect of fullerene C60 nanocrystals by suppression of autophagic degradation. Adv. Sci. 2019, 6, 1801233.
Wei, W. J.; Rosenkrans, Z. T.; Luo, Q. Y.; Lan, X. L.; Cai, W. B. Exploiting nanomaterial-mediated autophagy for cancer therapy. Small Methods 2019, 3, 1800365.
Chen, M. L.; Yang, D.; Sun, Y.; Liu, T.; Wang, W. H.; Fu, J. T.; Wang, Q. Q.; Bai, X. Q.; Quan, G. L.; Pan, X. et al. In situ self-assembly nanomicelle microneedles for enhanced photoimmunotherapy via autophagy regulation strategy. ACS Nano 2021, 15, 3387–3401.
Li, F. L.; Chen, T.; Wang, F.; Chen, J. F.; Zhang, Y. Y.; Song, D. T.; Li, N.; Lin, X. H.; Lin, L. S.; Zhuang, J. Y. Enhanced cancer starvation therapy enabled by an autophagy inhibitors-encapsulated biomimetic ZIF-8 nanodrug: Disrupting and harnessing dual pro-survival autophagic responses. ACS Appl. Mater. Interfaces 2022, 14, 21860–21871.
Wang, M.; Chen, Q.; Xu, D.; Yang, Z. B.; Chen, J. F.; Zhang, Y.; Chen, H. R. Self-cycling redox nanoplatform in synergy with mild magnetothermal and autophagy inhibition for efficient cancer therapy. Nano Today 2022, 43, 101374.
Schrezenmeier, E.; Dörner, T. Mechanisms of action of hydroxychloroquine and chloroquine: Implications for rheumatology. Nat. Rev. Rheumatol. 2020, 16, 155–166.
Ruan, S. B.; Xie, R.; Qin, L.; Yu, M. N.; Xiao, W.; Hu, C.; Yu, W. Q.; Qian, Z. Y.; Ouyang, L.; He, Q. et al. Aggregable nanoparticles-enabled chemotherapy and autophagy inhibition combined with anti-PD-L1 antibody for improved glioma treatment. Nano Lett. 2019, 19, 8318–8332.
Shen, W. T.; Zhang, X. Y.; Fu, X.; Fan, J. J.; Luan, J. Y.; Cao, Z. L.; Yang, P.; Xu, Z. Y.; Ju, D. W. A novel and promising therapeutic approach for NSCLC: Recombinant human arginase alone or combined with autophagy inhibitor. Cell Death Dis. 2017, 8, e2720.
Bellare, G. P.; Patro, B. S. Resveratrol sensitizes breast cancer to PARP inhibitor, talazoparib through dual inhibition of AKT and autophagy flux. Biochem. Pharmacol. 2022, 199, 115024.
Wang, Q.; Cheng, C. Q.; Zhao, S.; Liu, Q. Y.; Zhang, Y. H.; Liu, W. L.; Zhao, X. Z.; Zhang, H.; Pu, J.; Zhang, S. et al. A valence-engineered self-cascading antioxidant nanozyme for the therapy of inflammatory bowel disease. Angew. Chem., Int. Ed. 2022, 61, e202201101.
Wang, L. Y.; Zhu, B. H.; Deng, Y. T.; Li, T. T.; Tian, Q. Y.; Yuan, Z. G.; Ma, L.; Cheng, C.; Guo, Q. Y.; Qiu, L. Biocatalytic and antioxidant nanostructures for ROS scavenging and biotherapeutics. Adv. Funct. Mater. 2021, 31, 2101804.
Wu, J. J.; Wang, X. Y.; Wang, Q.; Lou, Z. P.; Li, S. R.; Zhu, Y. Y.; Qin, L.; Wei, H. Nanomaterials with enzyme-like characteristics (nanozymes): Next-generation artificial enzymes(II). Chem. Soc. Rev. 2019, 48, 1004–1076.
Wang, H.; Wan, K. W.; Shi, X. H. Recent advances in nanozyme research. Adv. Mater. 2019, 31, 1805368.
Huang, Y. Y.; Ren, J. S.; Qu, X. G. Nanozymes: Classification, catalytic mechanisms, activity regulation, and applications. Chem. Rev. 2019, 119, 4357–4412.
Jiang, D. W.; Ni, D. L.; Rosenkrans, Z. T.; Huang, P.; Yan, X. Y.; Cai, W. B. Nanozyme: New horizons for responsive biomedical applications. Chem. Soc. Rev. 2019, 48, 3683–3704.
Tang, G. H.; He, J. Y.; Liu, J. W.; Yan, X. Y.; Fan, K. L. Nanozyme for tumor therapy: Surface modification matters. Exploration 2021, 1, 75–89.
Zhao, S.; Li, Y. X.; Liu, Q. Y.; Li, S. R.; Cheng, Y.; Cheng, C. Q.; Sun, Z. Y.; Du, Y.; Butch, C. J.; Wei, H. An orally administered CeO2@montmorillonite nanozyme targets inflammation for inflammatory bowel disease therapy. Adv. Funct. Mater. 2020, 30, 2004692.
Tian, Z. M.; Li, X. H.; Ma, Y. Y.; Chen, T.; Xu, D. H.; Wang, B. C.; Qu, Y. Q.; Gao, Y. Quantitatively intrinsic biomimetic catalytic activity of nanocerias as radical scavengers and their ability against H2O2 and doxorubicin-induced oxidative stress. ACS Appl. Mater. Interfaces 2017, 9, 23342–23352.
Weng, Q. J.; Sun, H.; Fang, C. Y.; Xia, F.; Liao, H. W.; Lee, J.; Wang, J. C.; Xie, A.; Ren, J. F.; Guo, X. et al. Catalytic activity tunable ceria nanoparticles prevent chemotherapy-induced acute kidney injury without interference with chemotherapeutics. Nat. Commun. 2021, 12, 1436.
Tian, Z. M.; Zhao, J. L.; Zhao, S. J.; Li, H. C.; Guo, Z. X.; Liang, Z. C.; Li, J. Y.; Qu, Y. Q.; Chen, D. F.; Liu, L. Phytic acid-modified CeO2 as Ca2+ inhibitor for a security reversal of tumor drug resistance. Nano Res. 2022, 15, 4334–4343.
Naha, P. C.; Hsu, J. C.; Kim, J.; Shah, S.; Bouché, M.; Si-Mohamed, S.; Rosario-Berrios, D. N.; Douek, P.; Hajfathalian, M.; Yasini, P. et al. Dextran-coated cerium oxide nanoparticles: A computed tomography contrast agent for imaging the gastrointestinal tract and inflammatory bowel disease. ACS Nano 2020, 14, 10187–10197.
Soh, M.; Kang, D. W.; Jeong, H. G.; Kim, D.; Kim, D. Y.; Yang, W.; Song, C.; Baik, S.; Choi, I. Y.; Ki, S. K. et al. Ceria-zirconia nanoparticles as an enhanced multi-antioxidant for sepsis treatment. Angew. Chem., Int. Ed. 2017, 56, 11399–11403.
Karakoti, A.; Singh, S.; Dowding, J. M.; Seal, S.; Self, W. T. Redox-active radical scavenging nanomaterials. Chem. Soc. Rev. 2010, 39, 4422–4432.
Boey, A.; Leong, S. Q.; Bhave, S.; Ho, H. K. Cerium oxide nanoparticles alleviate hepatic fibrosis phenotypes in vitro. Int. J. Mol. Sci. 2021, 22, 11777.
Global Burden of Disease 2019 Cancer Collaboration. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: A systematic analysis for the global burden of disease study 2019. JAMA Oncol. 2022, 8, 420–444.
White, E. Deconvoluting the context-dependent role for autophagy in cancer. Nat. Rev. Cancer 2012, 12, 401–410.
Chae, Y. C.; Vaira, V.; Caino, M. C.; Tang, H. Y.; Seo, J. H.; Kossenkov, A. V.; Ottobrini, L.; Martelli, C.; Lucignani, G.; Bertolini, I. et al. Mitochondrial Akt regulation of hypoxic tumor reprogramming. Cancer Cell 2016, 30, 257–272.
Mirshafiee, V.; Sun, B. B.; Chang, C. H.; Liao, Y. P.; Jiang, W.; Jiang, J. H.; Liu, X. S.; Wang, X.; Xia, T.; Nel, A. E. Toxicological profiling of metal oxide nanoparticles in liver context reveals pyroptosis in Kupffer cells and macrophages versus apoptosis in hepatocytes. ACS Nano 2018, 12, 3836–3852.
Levine, B.; Kroemer, G. Biological functions of autophagy genes: A disease perspective. Cell 2019, 176, 11–42.
Moscat, J.; Karin, M.; Diaz-Meco, M. T. p62 in cancer: Signaling adaptor beyond autophagy. Cell 2016, 167, 606–609.
Yang, B. W.; Ding, L.; Yao, H. L.; Chen, Y.; Shi, J. L. A metal-organic framework (MOF) Fenton nanoagent-enabled nanocatalytic cancer therapy in synergy with autophagy inhibition. Adv. Mater. 2020, 32, 1907152.
Jang, J.; Wang, Y. D.; Lalli, M. A.; Guzman, E.; Godshalk, S. E.; Zhou, H. J.; Kosik, K. S. Primary cilium-autophagy-Nrf2 (PAN) axis activation commits human embryonic stem cells to a neuroectoderm fate. Cell 2016, 165, 410–420.
Tai, W. Y.; Li, J. W.; Corey, E.; Gao, X. H. A ribonucleoprotein octamer for targeted siRNA delivery. Nat. Biomed. Eng. 2018, 2, 326–337.
Chen, L. J.; Jiang, X. W.; Lv, M.; Wang, X. L.; Zhao, P. R.; Zhang, M.; Lv, G. L.; Wu, J. Y.; Liu, Y. Y.; Yang, Y. et al. Reductive-damage-induced intracellular maladaptation for cancer electronic interference therapy. Chem 2022, 8, 866–879.
京公网安备11010802044758号